Active: WST-057 4mL (146 mg pirenzepine free base monohydrate) topical solution for Peripheral Nervous System Diseases
This study is evaluating whether a drug may help improve pain for individuals with diabetes.
See full descriptionAbout the trial for Peripheral Nervous System Diseases
Treatment Groups
This trial involves 2 different treatments. Active: WST-057 4mL (146 Mg Pirenzepine Free Base Monohydrate) Topical Solution is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are in Phase 2 and have already been tested with other people.
Eligibility
This trial is for patients born any sex aged 18 and older. There are 10 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether Active: WST-057 4mL (146 mg pirenzepine free base monohydrate) topical solution will improve 4 primary outcomes, 3 secondary outcomes, and 2 other outcomes in patients with Peripheral Nervous System Diseases. Measurement will happen over the course of 12 weeks.
Patient Q & A Section
What are common treatments for peripheral nervous system diseases?
The treatment for PNSD was mainly conservative in nature. The mainstay of treatment for PNSD, in patients who present with lower limb weakness, is physiotherapy. In the case of muscle atrophy or limb loss, the mainstay of treatment was to place an immobilizer or an orthosis. Although no randomized trial was performed to assess the effectiveness and safety, evidence from many case series suggested that the combination therapy of botulinum toxin and oral rehabilitation is a viable option in treating spastic paraplegic patients suffering from spastic quadriplegia or spastic paraparesis. Elective surgery remained only as a second-line treatment option when the diagnosis was clear.
Can peripheral nervous system diseases be cured?
There is still poor knowledge of how peripheral nervous system diseases are created and how to prevent and treat them, and how to detect and diagnose diseases more easily. We can increase our knowledge and use more efficient treatments if we can use modern medical treatment as well as physical therapies to treat peripheral nervous system diseases. Thus, in order to cure peripheral nervous system diseases by using treatment, we should use different types and modes of treatments such as diet, pharmacological intervention or surgery.
How many people get peripheral nervous system diseases a year in the United States?
For most of the common peripheral nervous system diseases, more than one person per year in the United States suffers the disorder. The percentage of cases of polyneuritis and mononeuritis seems to decline with age and to be more common in men than women. The overall percentage of polyneuritis cases seem to be influenced by geographic distribution as well as by age.
What causes peripheral nervous system diseases?
The causes of peripheral nervous system disorders are varied and can include hereditary conditions, injuries and poisonings while work is the leading cause of PNS disorder. PNS diseases can be divided into specific categories including neurological disorders, vascular, endocrine, hematological & infectious disorders (Fisher's syndrome). There is also an associated association between specific illnesses and PNS disorders, such as diabetes and multiple sclerosis. Clinicians should have a heightened vigilance for detecting PNS disorders and consider the clinical scenario for each patient.
What is peripheral nervous system diseases?
The nervous system forms a major part of the total organism and plays an important role in most biological processes. PNS can be injured through disease and disease-causing agents. PNS disease is often a disease with a poor prognosis. A better understanding of the pathogenesis of PNS diseases is critical for developing appropriate therapy and optimizing the outcome.
What are the signs of peripheral nervous system diseases?
The most common signs of peripheral nervous system diseases are sensory and sensoromotor neuropathy signs. They are pain of radicular nature and numbness, weakness, and other sensory complaints. Muscle atrophy, wasting, and fasciculation may mimic the symptoms of the peripheral neuropathy, or muscle abnormalities may mimic the signs of a neuromuscular disease. In addition to the above-mentioned symptoms, some autonomic neuropathies may cause a generalized sympathetic symptomatology related to the sympathetic trunk or autonomic nerves. Muscle weakness, wasting, and fasciculation may be similar to that of peripheral neuropathy. However, the wasting, fasciculation, and wasting signs are caused by autonomic neuropathies.
What is the latest research for peripheral nervous system diseases?
PNS disease research is continuing unabated and we hope to learn more about peripheral nervous system [diseases] in the future. The most recent [research] can be found on [Power]](http://power.withpower.com/clinical-trials/) websites.
Who should consider clinical trials for peripheral nervous system diseases?
Peripheral nervous system diseases can be divided into two categories. One category is peripheral neuropathies caused by multiple neurogenic etiologies; the other category is chronic degenerative diseases of the peripheral nervous system. The majority of the research for peripheral neuropathy is focused on diabetic neuropathy and polyneuropathies. However, chronic degenerative diseases of the peripheral nervous system are just as important as diabetic neuropathy and polyneuropathies; therefore we should consider researching chronic degenerative diseases of the peripheral nervous system for treatment and diagnostics.
What is active: wst-057 4ml (146 mg pirenzepine free base monohydrate) topical solution?
In clinical studies comparing the effects of topical 4% pirenzepine to 4% and 2% aceponate solutions, subjects demonstrated improved pain relief at 4-8h at 7.4mg/g topical solution while a similar improvement was achieved with only 0.25% pirenzepine cream. Further studies are needed in order to compare pirenzepine 4% ointment and topical solution.
What is the average age someone gets peripheral nervous system diseases?
While peripheral nerves have a natural role in disease, there is no clear threshold at which the nerve is diseased. As such, PNS disease is not an appropriate term for the subset of nerves that are diseased. If a disorder is associated with [peripheral nervous system diseases], then one would likely also find a disorder associated with [peripheral nervous system diseases], and vice versa. The name [peripheral nervous system diseases] may thus be used to refer to neuropathy in both cases. A name unique to PNS disorders [such as peripheral neuropathies] should not be used for nerves and sensory pathways that can be associated with [peripheral nervous system disorders].
How serious can peripheral nervous system diseases be?
There is a low probability of serious conditions developing in patients who have [peripheral nervous system disease] (PNS) and [neuropathy] (NS). There is a higher than average chance to have both PNS and NS. There is a small chance of having serious conditions. There is an even lower chance of having serious conditions when either of these conditions is present alone. There is a higher than average chance of having other disorders, some of which are serious. There is a small chance of serious disorders developing alone or with both PNS and NS. Patients can minimize serious conditions or lessen their chances of getting serious conditions by staying healthy.
How does active: wst-057 4ml (146 mg pirenzepine free base monohydrate) topical solution work?
Topical pirenzepine 4 ml solution is a convenient topical patch application with a good safety profile in migraine patients. This may be a new treatment approach in migraine.